>
产品中心 >
Cell_transfection >
Signagen/GenJet In Vitro DNA Transfection Reagent for K562 Cells/SL100489-K562/0.5 mL
Description
GenJet DNA In Vitro
Transfection Reagent for K562 is pre-optimized for transfecting
K562 cells.
K562 cells were the first human immortalised myelogenous leukaemia line to be
established and are a bcr:abl positive erythroleukamia line derived from a 53
year old female CML patient in blast crisis. The cells are non-adherent and
rounded, and bear some proteomic resemblance to both undifferentiated
granulocytes and erythrocytes. In culture they exhibit much less clumping than
many other suspension lines, presumably due to the downregulation of surface
adhesion molecules by bcr:abl. K562s can spontaneously develop characteristics
similar to early-stage erythrocytes, granulocytes and monocytes and are easily
killed by natural killer cells as they lack the MHC complex required to inhibit
NK activity. They also lack any trace of Epstein-Barr virus and other
herpesviruses. In addition to the Philadelphia chromosome they also exhibit a
second reciprocal translocation between the long arm of chromosome 15 with
chromosome 17.
Refer to the following optimal transfection conditions for maximal transfection
efficiency on K562 cells. GenJet reagent, 1.0 ml, is sufficient for 300 to
600 transfections in 24 well plates or 50 to 100 transfections in 6 well plates.
Summary of
Optimal Transfection Conditions: |
|
Storage Condition
Store at 4 °C. If stored properly, the product is stable for 12 months or longer
Data Sheet